Assuntos
Antagonistas de Androgênios/uso terapêutico , Hormônio Liberador de Gonadotropina , Neoplasias da Próstata/tratamento farmacológico , Testosterona/sangue , Antagonistas de Androgênios/administração & dosagem , Quimioterapia Adjuvante/métodos , Terapia Combinada , Esquema de Medicação , Hormônio Liberador de Gonadotropina/agonistas , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Humanos , Masculino , Orquiectomia , Neoplasias da Próstata/sangue , Neoplasias da Próstata/cirurgiaRESUMO
Two isoforms of Dj-1 protein were identified using a proteomic study in tissue specimens from two groups of patients with confirmed benign prostate hyperplasia (BPH) and prostate cancer (PCa). Dj-1 was also found in the cell lines PC-3, DU-145, LNCaP, BPH-1, and the lowest level of Dj-1 was found in BPH-1. Immunochemical study (ELISA) of serum levels of Dj-1, Bcl-2, IGF-1 and IGFBP-3 proteins revealed statistically significant distinctions between two groups of patients (p=0,004, Mann-Whitney test) only for Dj-1. Taken together, these data suggest that Dj-1 protein is a perspective biomarker candidate for PCa.
Assuntos
Biomarcadores Tumorais/sangue , Peptídeos e Proteínas de Sinalização Intracelular/sangue , Proteínas Oncogênicas/sangue , Neoplasias da Próstata/sangue , Proteômica , Linhagem Celular Tumoral , Humanos , Masculino , Proteína Desglicase DJ-1RESUMO
Benign prostatic hyperplasia and prostatic cancer have a significant effect of men's health, quality of life and death rate. Recent researches propose algorithms for treatment of benign prostatic hyperplasia which help determine optimal management of the disease using either alpha-adrenoblocker or combined therapy basing on factors of progression risk. Molecular-genetic, biological investigations reveal pathological prosesses leading to onset of the above pathological conditions thus opening prospects for prophylaxis of both benign and malignant prostatic hyperplasia. Further studies will specify efficacy and safety of 5-alpha reductase inhibitors in prevention of prostatic cancer.